Educational material about research reagents; not medical advice, diet coaching, or human-use instructions.
The query "peptides for weight loss" is the commercial goal phrase for this navigational shelf. Trademarks ("Ozempic", "Mounjaro", "Saxenda") and INNs ("semaglutide", "tirzepatide", "GLP-1") carry different search intent and on this page route to hub wiki/editorial or Incretin RUO, not a "best peptide" ranking. One topic bucket still mixes mono-GLP-1 agonists, dual GIP/GLP-1 molecules, triple agonists with glucagon, prescription drug trademarks, recovery peptides (BPC/TB), IGF/myostatin (muscle), longevity bioregulators, and lab RUO vials. Longeva hub does not sell a "weight-loss program" or rank a "best weight-loss peptide". This page is a shelf map of the GLP-1 / incretin cluster: who owns the commercial aisle, where hub wiki and editorial pillars live, the three receptor sub-aisles (mono, dual, triple), and where the research use only (RUO) boundary sits.
Who owns the GLP-1 aisle across the Longeva network
| Layer | Where | What you get |
|---|---|---|
| Incretin incretin agonists RUO catalog | Incretin · GLP-1 / incretin | Semaglutide, tirzepatide, liraglutide as research samples + COA |
| Incretin goal-shelf (deep guide) | how to read the Incretin catalog | Molecule table, LOT/COA, procurement router without a "best" ranking |
| Hub wiki · three incretin axes | GLP-1, GIP and glucagon | Educational primer: mono vs dual vs triple, no clinical promises |
| Hub editorial · Ozempic ↔ semaglutide | Ozempic ↔ semaglutide | Trademark vs INN, pharmacy brand vs RUO sample boundary |
| Hub editorial · Saxenda ↔ liraglutide | Saxenda ↔ liraglutide | Same for liraglutide; hub editorial, not Incretin commerce |
| Hub editorial · Mounjaro ↔ tirzepatide | Mounjaro ↔ tirzepatide | Dual GIP/GLP-1 context; apex editorial (not a broken Incretin link) |
| Triple agonist (separate class) | Tripept · retatrutide, wiki | GLP-1 + GIP + glucagon; not GLP-1-only or dual-only |
| Recovery hub (different aisle) | peptides for recovery | BPC/TB/healing-regeneration, not incretin shelf |
| Muscle hub (different aisle) | peptides for muscle, Regena | IGF/myostatin, different biological task |
| Longevity hub (different aisle) | peptides for longevity, Evity | Bioregulators / anti-aging RUO, not the weight-loss metabolic aisle |
Incretin is the canonical owner of GLP-1 / incretin SKUs in our network. Hub stays editorial + navigation without a buy CTA on Incretin SKUs. Tripept runs triple-agonist retatrutide separately from the Incretin dual/mono line.
Three incretin sub-aisles: GLP-1 mono, dual GIP/GLP-1, triple agonist
The "peptides for weight loss" aisle in casual search often merges different receptor profiles into one "GLP-1 for weight loss" bucket. In the Longeva/Incretin/Tripept catalog they map to distinct molecules:
- GLP-1 mono (mono-agonist). Semaglutide and liraglutide act mainly on the GLP-1 receptor. Trademark lines Ozempic/Wegovy (semaglutide) and Saxenda/Victoza (liraglutide) describe finished drug products; an Incretin RUO sample is the same INN without pharmacy labeling. Clinical programs STEP (semaglutide) and SCALE (liraglutide) studied branded forms inside trial protocols, not an arbitrary RUO batch.
- Dual GIP/GLP-1 (dual incretin agonist). Tirzepatide adds a GIP axis to GLP-1. Mounjaro and Zepbound are trademark names for tirzepatide in prescription forms; hub editorial: Mounjaro ↔ tirzepatide. SURPASS and SURMOUNT describe the dual-agonist class in clinic, not a protocol for an RUO vial.
- Triple agonist (GLP-1 + GIP + glucagon). Retatrutide on Tripept activates a third axis (glucagon) on top of the dual profile. That is an adjacent research cluster, not an Incretin GLP-1 mono/dual subcategory. Map of all three axes: GLP-1, GIP and glucagon.
Mono, dual, and triple are different molecule classes with different protocol readouts. This map does not answer "which works better for weight loss"; it routes queries to wiki, editorial, and RUO cards.
Semaglutide, tirzepatide, liraglutide: where to read about each
| Sub-aisle | Molecule (INN) | Hub wiki | Hub PDP | Incretin RUO | Hub editorial |
|---|---|---|---|---|---|
| GLP-1 mono | Semaglutide | wiki | PDP | card | Ozempic ↔ semaglutide |
| GLP-1 mono | Liraglutide | wiki | PDP | card | Saxenda ↔ liraglutide |
| Dual GIP/GLP-1 | Tirzepatide | wiki | PDP | card | Mounjaro ↔ tirzepatide |
Full Incretin category: Weight loss / GLP-1 (incretins). Two-molecule comparison in catalog: tirzepatide vs semaglutide (Incretin procurement router). Neutral hub reference without buy CTA: hub PDPs name the INN; commerce lives on Incretin.
RUO framing (why "weight-loss peptide" ≠ "weight-loss drug")
- A RUO vial carries INN and fill weight; COA (certificate of analysis) describes batch analytics (identity, purity, assay), not medical fitness or a "weight-loss result".
- Ozempic, Saxenda, Mounjaro, Wegovy, Zepbound, Victoza, Rybelsus are trademarks for finished drug products with medical labeling, prescriptions, and regulatory status. A different product class from lyophilized research material.
- Clinical programs (STEP, SCALE, SURPASS, SURMOUNT) describe drug trials inside trial protocols, not an arbitrary RUO batch sharing the molecule name.
- "Weight loss", "GLP-1 for weight", and "Ozempic analogue" in marketing describe the search topic, not a verified vial effect outside a lab protocol.
- Longeva hub does not publish diet protocols, "courses", or "stacks"; editorial explains the molecule class and brand vs INN boundary, Incretin sells RUO material with COA.
Network-wide brand chooser: buy peptides · pick a brand.
Queries that only look like weight loss
Four common merges inside one "peptides for weight loss" query:
| Query / topic | Actual destination | Why not weight-loss shelf |
|---|---|---|
| BPC-157, TB-500, "joint / recovery peptides" | hub · recovery, Regena · healing | Repair/healing-regeneration, not incretin metabolic axis |
| IGF-1 LR3, myostatin, "muscle peptides" | hub · muscle growth, Regena · muscle | IGF-1R / ActRII signaling, not GLP-1/GIP |
| Epitalon, MOTS-c, "longevity peptides" | hub · longevity, Evity · longevity | Bioregulators / anti-aging RUO, different goal |
| Retatrutide, "triple GLP-1" | Tripept · retatrutide, wiki | Triple agonist on Tripept, not Incretin mono/dual line |
Why identity matters more than purity for incretins
COA reading works differently on the incretin aisle, for a specific reason: high purity does not prove the vial holds the molecule you ordered. A sample can be 99% pure and still be a different peptide.
- Purity answers "how much foreign material", identity answers "what is this". An HPLC (high-performance liquid chromatography) chromatogram shows one main peak and its share of total peak area. A peak that eluted at the expected time does not by itself name the substance.
- Molecules on this aisle are structurally close. Semaglutide and liraglutide are both acylated GLP-1 analogues differing mainly in the lipid chain and linker. Tirzepatide is a 39-amino-acid peptide with a different C-terminus. Under similar gradient conditions the retention times of such compounds can sit close together, so a clean peak without an identity confirmation still leaves substitution possible.
- What actually settles it. Mass spectrometry comparing measured molecular mass against the theoretical mass for the declared INN, plus retention-time agreement with a reference standard. In the report that is a separate identity section, not the purity line.
- Peptide content versus vial weight. A lyophilizate contains counter-ion and excipients. "5 mg" on the label is fill weight, not necessarily net peptide; net peptide content is its own figure.
- LOT match. The vial batch number must match the PDF in the COA archive; verify a lot at
/verify/{lot}(public COA plus a PIN for the per-unit verdict).
Practical takeaway for this aisle: the word "Ozempic" or "Mounjaro" in a listing is not data. Ask for the identity section, not only the purity number, because identity is what separates semaglutide from anything that behaves like it on a column.
Four mistakes in weight-loss queries
- "Best peptide for weight loss" or "semaglutide vs tirzepatide: which is better". Hub does not rank efficacy. Identify the receptor profile first (mono GLP-1 vs dual GIP/GLP-1 vs triple), then open wiki/editorial for that INN. Sample comparison in catalog lives on Incretin (tirzepatide vs semaglutide), not on hub apex.
- Mix trademark with INN on an RUO vial. A query for "buy Ozempic" often means the pharmacy brand; an RUO vial should read semaglutide. Hub editorial splits the pairs: Ozempic, Saxenda, Mounjaro.
- Read clinical trial percentages as a Telegram-vial promise. Published trial numbers describe the studied drug inside a trial protocol, not an unlabeled RUO powder. Clinical context ≠ instructions for RUO material.
Molecule reference for the incretin aisle
- GLP-1, GIP and glucagon (three incretin axes)
- Semaglutide · Liraglutide · Tirzepatide · Retatrutide
- Neutral hub PDP: semaglutide, liraglutide, tirzepatide (buy on Incretin)
Where to read next
- Incretin · commercial goal-shelf (RUO)
- Wiki primer · three incretin axes
- Ozempic ↔ semaglutide · Saxenda ↔ liraglutide · Mounjaro ↔ tirzepatide
- Recovery navigational shelf · Muscle shelf · Longevity shelf
- How to pick a brand in the Longeva network
Longeva hub · navigational only · does not replace a lab protocol. Ozempic®, Wegovy®, Rybelsus®, Saxenda®, Victoza®, Mounjaro®, Zepbound® are Novo Nordisk and Eli Lilly trademarks; Longeva is not affiliated with those manufacturers.
